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Background: Experimental and clinical data suggest that solid cancers contain treatment-resistant cancer stem cells
that will impair treatment efficacy. The objective of this study was to investigate if head and neck squamous cell
carcinoma (HNSCC) also contain cancer stem cells that can be identified by low 26S proteasome activity and if their
presence correlates to clinical outcome.
Methods: Human HNSCC cells, engineered to report lack of proteasome activity based on accumulation of a
fluorescent fusion protein, were separated based on high (ZsGreen-cODCneg) or low (ZsGreen-cODCpos) proteasome
activity. Self-renewal capacity, tumorigenicity and radioresistance were assessed. Proteasome subunit expression was
analyzed in tissue microarrays and correlated to survival and locoregional cancer control of 174 patients with HNSCC.
Results: HNSCC cells with low proteasome activity showed a significantly higher self-renewal capacity and increased
tumorigenicity. Irradiation enriched for ZsGreen-cODCpos cells. The survival probability of 82 patients treated with
definitive radio- or chemo-radiotherapy exhibiting weak, intermediate, or strong proteasome subunit expression were
21.2, 28.8 and 43.8 months (p = 0.05), respectively. Locoregional cancer control was comparably affected.
Conclusions: Subpopulations of HNSCC display stem cell features that affect patients’ tumor control and survival.
Evaluating cancer tissue for expression of the proteasome subunit PSMD1 may help identify patients at risk for relapse.
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Radiotherapy is standard of care for advanced stage head
and neck squamous cell carcinoma (HNSCC). However,
despite high total radiation doses combined with aggres-
sive chemotherapy the prognosis of these patients remains
poor.
First introduced a century ago by Paget [1] the cancer
stem cell hypothesis suggests that, similar to leukemia,
solid cancers are organized hierarchically with a small
number of cancer stem cells (CSCs) able to regrow a can-
cer and give rise to heterogeneous progeny, which lack* Correspondence: fpajonk@mednet.ucla.edu
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unless otherwise stated.these cancer stem cell traits [2]. Therefore, elimination of
all CSCs from a tumor is a sine qua non for cancer cure.
After a landmark paper by Al-Hajj and colleagues [3] that
reported prospective identification of breast cancer stem
cells, several follow-up studies provided strong clinical
[4-6] and preclinical [7-10] evidence for the existence and
relevance of cancer stem cells in breast cancer and glioma.
The cancer stem cell hypothesis received further strong
support from elegant animal experiments demonstrating
the existence of cancer stem cells in undisturbed murine
tumors of the GI system [11], brain [12] and skin [13]. We
and others have reported that CSCs are in general resist-
ant to established chemotherapeutic agents and are rela-
tively radioresistant [14-18]. Thus, established treatment
regimens should be re-evaluated based on their ability to
kill CSCs. However, a prerequisite for such testing is the
ability to identify CSCs.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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relatively well defined for breast cancer [3,19-21] and gli-
oma [7,9,10,21] while CSC markers for other solid can-
cers are still subject of ongoing research. A previous
study suggested that CSCs in HNSCC could be pro-
spectively identified using antibodies against the surface
marker CD44 [22]. However, because CD44 is ubiqui-
tously expressed in various isoforms, the value of CD44
as a CSC marker is controversially discussed [23]. In
combination with ALDH1 staining and use of the side
population CD44 still seems to be a useful marker for
the prospective identification of CSCs in HNSCC [24].
We recently reported that lack of proteasome function
and subunit expression is a feature of therapy-resistant,
tumorigenic cells in breast cancer and glioma [16,21,25],
therefore we hypothesized that HNSCCs could contain a
similar cell population.
Here we report that HNSCC cell lines, indeed, contain
a small population of radioresistant cells with high self-
renewal capacity that can be prospectively identified
based on their intrinsic low proteasome function. Fur-
thermore, we demonstrate that a weak expression of the
proteasome subunit PSMD1 in HNSCC cells predicts
unfavorable outcome after radiotherapy.
Methods
Cell culture
Human UM-SCC4, UM-SCC6, UM-SCC12, UM-SCC-
17B, FaDu, and Cal33 head and neck squamous carcinoma
cell lines were a kind gift of Steven Wong (Department of
Hematology/Oncology at UCLA) and have been previ-
ously described elsewhere [26]. ZsGreen-cODC expressing
cells were obtained as described in Vlashi et al. [21].
Briefly, cells were infected with a retroviral vector coding
for a fusion protein between the fluorescent protein
ZsGreen and the C-terminal degron of murine ornithine
decarboxylase. The latter targets ZsGreen to ubiquitin-
independent degradation by the 26S proteasome, thus
reporting lack of proteasome function through accumula-
tion of ZsGreen-cODC. Infected cells were selected for
five days using G418. Successful complete infection was
verified using the proteasome inhibitor MG132 (Sigma,
MO). All cell lines were cultured in log-growth phase in
DMEM (Invitrogen, Carlsbad, CA) (supplemented with
10% fetal bovine serum and penicillin and streptomycin
cocktail). All cells were grown in a humidified atmosphere
at 37°C with 5% CO2.
Irradiation
Cells grown as monolayer or sphere cultures were irradi-
ated at room temperature using an experimental X-ray
irradiator (Gulmay Medical Inc. Atlanta, GA) at a dose
rate of 5.519 Gy/min for the time required to apply a
prescribed dose. The x-ray beam was operated at 250 kVand hardened using a 4 mm Be, a 3 mm Al, and a
1.5 mm Cu filter. Corresponding controls were sham
irradiated.
Flow cytometry
We had previously shown that breast cancer stem cells
could be identified via their low proteasome activity
[16,21], which can be assessed by analyzing ZsGreen-
cODC protein accumulation. Five days after radiation,
cells were trypsinized and ZsGreen-cODC expression
was assessed by flow cytometry. Cells were defined as
“ZsGreen-cODC positive” if the fluorescence in the FL-
1H channel exceeded the fluorescence level of 99.9% of
the empty vector-transfected control cells.
Experiments were performed using a MACSquant
Analyzer (Miltenyi Biotech, CA) and analyzed using the
FloJo software package (vers. 9, Tree Star Inc., OR).
For ALDH1 staining, cells were fixed in 4% parafor-
maldehyde for 20 min at room temperature. Non-
specific binding was blocked by incubating the fixed cells
for 1 hour in PBS/1% BSA/0.1% Tween-20/10% goat
serum at room temperature. Cells were then incubated
with a mouse anti-ALDH-1 antibody (Abcam, Cambridge,
MA) at 4°C overnight (1:100 dilution). After washing off
the non-bound primary antibody, the cells were incubated
with an anti-mouse-Cy5 secondary antibody (Abcam,
Cambridge, MA) in blocking buffer for 2 hours at room
temperature. Cells were then washed with PBS and ana-
lyzed on BD FACSAria.
Sphere-forming assay
To assess sphere forming capacity, cells were trypsinized
and plated in sphere media (DMEM-F12, 0.4% BSA
(Sigma), 10 ml/500 ml B27 (Invitrogen) 5 μg/ml bovine
insulin (Sigma), 4 μg/ml heparin (Sigma), 20 ng/ml
fibroblast growth factor 2 (bFGF, Sigma) and 20 ng/ml
epidermal growth factor (EGF, Sigma)) into 96-well
ultra-low adhesion plates, ranging from 1 to 256 cells/
well. Growth factors, EGF and bFGF, were added every
3 days, and the cells were allowed to form spheres for
21 days. The number of spheres formed per well was
then counted and expressed as a percentage of the initial
number of cells plated. Three independent experiments
were performed.
Animals
Nude (nu/nu), 6-8-week-old female mice, originally ob-
tained from The Jackson Laboratories (Bar Harbor, ME)
were re-derived, bred and maintained in a pathogen-free
environment in the American Association of Laboratory
Animal Care-accredited Animal Facilities of Department
of Radiation Oncology, University of California (Los
Angeles, CA) in accordance to all local and national
guidelines for the care of animals.
Table 1 HNSCC, definitive radio- radiochemotherapy by
PSMD1-score
PSMD1-score 1 (n=29) 2 (n=26) 3 (n=27)
Age (years) mean 59.5 62.1 59.3
Q1/Q2/Q3 54/59/65 56/61.5/69.7 55/60/63
Male (%) 96.5 84.6 92.5
Weight (kg) mean 72.7 72.0 71.7
Q1/Q2/Q3 60/67/81 61.5/66/79 64.5/72/80
Smoker (n) 17/26 19/24 20/26




Q1/Q2/Q3 11.9/12.9/14 12.8/13.7/14.1 12.4/13.5/14.4
Oral cavity n (%) 4 (13.7) 3 (11.5) 5 (18.5)
Oropharynx n (%) 13 (44.8) 9 (34.5) 9 (33.3)
Hypopharynx n (%) 10 (34.4) 11 (42.2) 8 (29.6)
Larynx n (%) 2 (6.8) 3 (11.5) 5 (18.5)
cT1 n (%) 1 (3.4) 1 (3.8)
cT2 n (%) 2 (6.8) 3 (11.5) 4 (14.8)
cT3 n (%) 11 (37.9) 6 (23.0) 7 (25.9)
cT4 n (%) 15 (51.7) 16 (61.5) 16 (59.2)
cN0 n (%) 2 (6.8) 4 (15.3) 3 (11.1)
cN1 n (%) 6 (20.6) 1 (3.8) 1 (3.7)
cN2 n (%) 19 (65.3) 20 (76.8) 21 (57.7)
cN3 n (%) 2 (6.9) 1 (3.8) 2 (7.4)
G1 n (%) 2 (6.8) 2 (7.6)
G2 n (%) 12 (41.3) 17 (65.3) 14 (53.8)
G3 n (%) 15 (51.7) 7 (26.9) 12 (46.1)
EpoR (C20+) (%) 19 (65.5) 18 (69.2) 22 (81.4)
RT (Gy) mean 71.1 69.7 67.7
Q1/Q2/Q3 70/70.6/72 69.9/70/70.6 70/70/70.6
RT (days) 48.1 47.5 45.0









21.2; 10.5-28.7 28.8; 6.3-42.4 43.8; 12.4-
Lagadec et al. BMC Cancer 2014, 14:152 Page 3 of 11
http://www.biomedcentral.com/1471-2407/14/152Tumor xenotransplantation
UM-SCC12-ZsGreen-cODC-negative, derived from mono-
layer cultures, and UM-SCC12-ZsGreen-cODC-positive
cells derived from sphere cultures and sorted by
fluorescence-activated cell sorting, were injected subcuta-
neously into the thighs and shoulders of 6-week old
female Nu/Nu mice (105, 104, 103, or 102 cells per inocu-
lum) within Matrigel (BD Biosciences). Tumor growth
was assessed on a weekly basis, and the mice were sacri-
ficed when the tumor size reached tumor diameters re-
quiring euthanasia.
Patients
Records and formalin fixed tissue blocks from patients
with HNSCC irradiated between January 1997 and
November 2002 were evaluated within prospective clin-
ical trials [27-30] at the University Hospital Freiburg,
Germany (Table 1). Patients were originally selected to
investigate the prognostic significance of blood hemo-
globin levels and cellular EpoR-expression on clinical
outcome. This report will focus on data of 82 patients
who received definitive radiotherapy [27,28] or radioche-
motherapy [29,30] alone. Patients were older than
18 years and had histologically proven advanced (T3, T4,
or nodal involvement) squamous-cell carcinoma of the
oral cavity, oropharynx, hypopharynx, or larynx. For
comparison, data from 92 additional patients with ad-
vanced HNSCC but receiving postoperative radiation
within three of the above mentioned trials [27,29,30] will
be given in Table 2.
All trials were approved by the ethic committee of the
University Hospital, Freiburg, Germany and done in ac-
cordance with the revised Declaration of Helsinki and
good clinical practice guidelines. All patients provided
written informed consent. The present study was add-
itionally approved by the institutional review board of
the University Hospital, Freiburg, Germany and the Uni-
versity of California, Los Angeles, USA.
Conventional or three-dimensional planning tech-
niques were used for radiotherapy. The planning target
volume (PTV) included the gross tumor volume (GTV)
or tumor bed with a 1–2 cm safety margin and the re-
gional lymph-node areas. 6 mega electron volt linear ac-
celerators were used and standard dose and fractionation
protocols (five fractions of 2.0 Gy or 1.8 Gy per week)
were followed. A total dose of 60 Gy (allowable range 56–
64 Gy) was prescribed to regions for R0 or R1 resected
disease, and 70 Gy (allowable range 66–74 Gy) for primary
definitive treatment or to macroscopically incompletely
resected tumor (R2) and/or lymph nodes exceeding 2 cm.
50 Gy were administered to uninvolved nodal regions.
The spinal cord was shielded after 30–36 Gy.
Follow-up was performed quarterly for the first two
years, every six months for up to five years andcontinuously thereafter on a yearly basis. Locoregional
tumor control and survival was assessed.
Tissue microarrays
Tissue microarrays (TMAs) and immune-histochemical
staining were used to analyze the expression of the prote-
asome subunit PSMD1 as previously described [21,25].
Briefly, TMA enables tumor tissue samples from different
Table 2 HNSCC, postoperative radio- radiochemotherapy
by PSMD1-score
PSMD1-score 1 (n=26) 2 (n=27) 3 (n=39)
Age (years) mean 63.4 60.8 60.2
Q1/Q2/Q3 58.5/64/70.2 52/60/70 51/61/68
Male (%) 88.4 81.4 73.6
Weight (kg) mean 64.9 68.8 67.7
Q1/Q2/Q3 57.8/64.5/73 56.8/68.8/77.5 57.8/68.7/77.6







Q1/Q2/Q3 12.0/12.6/13.6 11.1/13.1/14 11.2/11.9/12.9
Unknown primary 1 (3.7)
Oral cavity n (%) 7 (26.9) 8 (29.6) 9 (23.0)
Oropharynx n (%) 9 (34.6) 10 (37.0) 16 ( 41.0)
Hypopharynx
n (%)
5 (19.2) 2 (7.4) 8 (20.5)
Larynx n (%) 5 (19.2) 6 (22.2) 6 (15.3)
cT0 n (%) 1 (3.8) 3 (7.6)
cT1 n (%) 7 (26.9) 2 (7.6) 7 (17.9)
cT2 n (%) 8 (30.7) 8 (30.7) 11 (28.2)
cT3 n (%) 6 (23.0) 6 (23.0) 11 (28.2)
cT4 n (%) 5 (19.2) 9 (34.6) 7 (17.9)
cN0 n (%) 2 (7.6) 6 (22.2) 5 (12.8)
cN1 n (%) 5 (19.2) 4 (14.8) 14 (35.8)
cN2 n (%) 18 (69.2) 14 (51.8) 19 (48.6)
cN3 n (%) 1 (3.8) 3 (11.1) 1 (2.5)
G1 n (%) 1 (3.7) 1 (2.5)
G2 n (%) 12 (46.1) 15 (55.5) 21 (53.8)
G3 n (%) 14 (53.8) 11 (40.7) 17 (43.5)
EpoR (C20+) (%) 17 (65.3) 24 (88.8) 26 (66.6)
RT (Gy) mean 62.9 63.9 62.2
Q1/Q2/Q3 60/64/64 63/64/66 60/63/64
RT (days) 46.9 46.3 45.7









48.2; 12.4-92.6 29.3; 13–74.1 42.8; 20.7-66.2
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mm needle was used to construct the array by extracting
representative tumor tissue cores from each formalin-
fixed, paraffin-embedded tissue blocks of HNSCC. TMAslides were counterstained with hematoxylin to visualize
nuclei. PMSD1-expression analysis was performed by two
pathologists who were unaware of the findings of the clin-
ical data. A score of 1 was considered as ‘weak expression’,
2 was considered as ‘intermediate expression’, and a score
of 3 was considered ‘strong expression’.
Statistics
All experimental results are expressed as mean values. A
p-value of ≤ 0.05 in a Student's t-test was considered to
indicate statistically significant differences. The test was
applied to normalized data to compensate for the vari-
ance of measurements between biologically independent
replicates of the same experiments. CSC frequencies and
p values were calculated using the Extreme Limiting Di-
lution Analysis (ELDA) software based on the algorithm
defined by Hu and Smyth [31] (http://bioinf.wehi.edu.
au/software/elda/). We confirmed that our data fits a
single-hit linear model assumption by a likelihood ratio
test to analyze goodness of fit.
The frequency of demographic and intervention pa-
rameters were descriptively determined in patients with
different PSMD1-scores and locoregional tumor control
and survival were assessed with Kaplan-Meier estimates
within the different patient groups. Two-sided log-rank
statistics were performed.
Results
HNSCC cells with low proteasome activity show increased
self-renewal capacity
We had previously shown that breast cancer and glioma
cells with low proteasome activity had a cancer stem cell
phenotype, exhibiting increased self-renewal capacity
and tumorigenicity [21]. Therefore we sought to explore
if cells with intrinsically low proteasome activity could
also be found in HNSCCs.
In order to assess proteasome activity in HNSCC lines
we engineered UM-SCC4, UM-SCC6, UM-SCC12, UM-
SCC-17B, Cal33 and FaDu cells to report the activity of
this protease by accumulation of a fusion protein between
the fluorescent protein ZsGreen and the C-terminal
degron of murine ornithine decarboxylase (cODC). The
latter directs the fusion protein to ubiquitin-independent
degradation by the 26S proteasome. Therefore, cells with
low proteasome activity accumulate the fluorescent fusion
protein.
When cells were kept as monolayer cultures, a low
number of cells accumulated the fusion protein, thus in-
dicating the presence of a small subpopulation of cells
with intrinsically low proteasome activity (Figure 1a).
When the UM-SCC6-ZsGreen-cODC and UM-SCC12-
ZsGreen-cODC cells were grown in suspension as
spheres in serum-free media supplemented with growth
factors, the cultures were enriched in ZsGreen-cODCpos
Figure 1 (See legend on next page.)
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Figure 1 HNSCC cell lines contain cell populations with low proteasome activity and higher sphere-forming capacity. HNSCC cell lines
were engineered to express the fusion protein ZsGreen and the c-terminal of the degron ornithine decarboxylase (cODC). (a) Cell lines were
cultured in log-growth phase in DMEM, and representative bright field and green fluorescent pictures of monolayer cells are shown. (b) The
percentage of ZsGreen-cODCpos cells increases when HNSCC cells are cultured in serum-free media as tumorspheres. (c) Percentage of cells forming
spheres from the ZsGreen-cODCneg (ZsG-) and ZsGreen-cODCpos (ZsG+) population after sorting by flow cytometry into 96-well plates. Means ± SD
from four independent experiments are shown. (d) Representative CD44 staining of a HNSCC patient-derived tumor sample. Tumor cells show uniform
membrane staining for CD44 (red). Nuclei are counterstained with DAPI (blue). (e) and (f) Flow cytometry analysis of ZsGreen accumulation (Y-axis)
and ALDH1 expression (X-axis) in UM-SCC-6 and UM-SCC-12 cells). ZsGreen-cODCpos cells with low proteasome activity are a subpopulation of ALDH1-
expressing cells with 19% of ZsGreen-cODCpos UM-SCC-6 cells and 41.5% of UM-SCC-12 cells positive for ALDH1.
Table 3 In vivo limiting dilution assay for UM-SCC12 cells
UM-SCC12-ZsGreen-cODC





1,000,000 4/4 Not performed
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0.12 ± 0.008;% UM-SCC6-ZsGreen-cODCpos from spheres:
0.812 ± 0.19, p = 0.005, n = 4; (% UM-SCC12-ZsGreen-
cODCpos from monolayer: 0.655 ± 0.42;% UM-SCC12-
ZsGreen-cODCpos from spheres: 5.24 ± 0.97; p = 0.02, n =
4, two-sided Student’s t-test; Figure 1b). These growth
conditions select for stem cells, while cells with limited
proliferative potential die by anoikis. Furthermore, we
sorted the UM-SCC6-ZsGreen-cODC and UM-SCC12-
ZsGreen-cODC cells into ZsGreen-cODCneg (high prote-
asome activity) and ZsGreen-cODCpos (low proteasome
activity) via FACS, and seeded these populations of cells
into ultra-low adhesion plates in an in vitro limiting dilu-
tion assay (256 to 1 cells/well) under serum-free condi-
tions and allowed for formation of tumor spheres. The
sphere-forming capacity of these two subpopulations of
cells differed in the two cell lines, however the ZsGreen-
cODCpos cells from both lines showed a significantly
higher self-renewal capacity compared to the ZsGreen-
cODCneg cells (sphere forming capacity of UM-SCC6-
ZsGreen-cODCpos 9.15 ± 1.26%; UM-SCC6-ZsGreen-cO
DCneg 4.77 ± 0.76% p = 0.041, n = 3; sphere forming cap-
acity of UM-SCC12-ZsGreen-cODCpos 0.88 ± 0.097%;
UM-SCC12-ZsGreen-cODCneg 0.038 ± 0.038% p = 0.0001,
n = 4, two-sided Student’s t-test; Figure 1c). This data
suggested that HNSCC are organized hierarchically or at
least are heterogeneous with respect to their ability to
self-renew.
In order to test if ZsGreen-cODCpos cells in HNSCC
overlap with cells positive for other established CSCs
markers, HNSCC tumor sections were stained against
CD44. CD44 caused a rather uniform membrane staining
of the tumor cells (Figure 1d), which did not reflect the
level of tumorigenicity seen in HNSCC xenografts studies.
The ZsGreen-cODC system cannot be used in com-
bination with the Aldefluor assay, which uses a green-
fluorescent substrate and therefore UM-SCC-6 and
UM-SCC-12 cells were stained with an antibody against
ALDH1 as described previously [20]. In both cell lines
ZsGreen-cODCpos cells with low proteasome activity were
a subpopulation of ALDH1-expressing cells (Figure 1e and f).
To further confirm the tumor-initiating properties of
the ZsGreen-cODC-positive population of cells weassessed the tumorigenicity of ZsGreen-cODCpos and
ZsGreen-cODCneg cells in vivo. When UM-SCC12-
cODC cells were injected into female nude mice,
ZsGreen-cODCpos showed a 20-fold higher tumorigen-
icity than ZsGreen-cODCneg cells, thus suggesting that
HNSCC cells with low proteasome activity are indeed
highly enriched for CSCs (Table 3). The estimated fre-
quencies of CSCs were 1 in 175,145 (CI: 410455 –
74737) in the ZsGreen-cODCneg cell population and 1 in
48,942 (CI: 127,609 – 18,771) in the ZsGreencODCpos
cell population with ZsGreen-cODCpos cells containing
significantly more CSCs (p = 0.0315, Chi-Square test).Radiation treatment enriches for HNSCC cells with low
proteasome activity
Next, we tested if cells with intrinsically low proteasome
activity would be intrinsically radioresistant. All the cell
lines were seeded as monolayer cultures and treated with
5 daily fractions of 3 Gy. The number of ZsGreen-
cODCpos cells was assessed 72 hours after the last fraction
of radiation, thus simulating a typical week of radiation
treatment followed by a weekend gap. In all cell lines,
fractionated radiation caused a significant increase in
the percentage of ZsGreen-cODCpos cells, suggesting
that cells with low proteasome activity are indeed in-
trinsically radioresistant (Figure 2a and e). When the
two different growth conditions were tested (monolayer vs.
sphere media) with the UM-SCC-12-ZsGreen-cODC and
UM-SCC-6-ZsGreen-cODC cells, the radiation-induced
increase in ZsGreen-cODCpos cells was seen regardless of
the culture conditions chosen (Figure 2a and b).
Figure 2 Radiation enriches for cells with low proteasome activity and increases self-renewal capacity. (a) HNSCC cells stably expressing
the ZsGreen-cODC fusion protein were grown as monolayers cultures and treated with 5 daily fractions of 3 Gy. The number of ZsGreen-cODCpos
cells was assessed 72 hours after the last fraction of radiation using flow cytometry. Shown are mean percentages of ZsGreen-cODCpos cells with
standard deviation (SD). (b) Treatment of UM-SCC-6-ZsGreen-cODC and UM-SCC-12-ZsGreen-cODC sphere cultures were treated with 5 fractions
of 3 Gy, also resulting in enrichment of ZsGreen-cODCpos cells with low proteasome activity. This effect was more pronounced in radiosensitive
[39] UM-SCC-6 cells than in radioresistant [40] UM-SCC12 cells. (c and d) 72 hours after the last fraction of radiation, cells were plated in 96-well
plates at clonal densities to assess self-renewal capacity. Mean (± SD) percentages of cells forming a sphere with are shown. (e) Representative
FACS analysis of HNSCC cell lines (monolayer) after treatment with 0 or 5×3 Gy.
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HNSCC cells
Next we assessed if radiation-induced increases in the
number of ZsGreen-cODCpos cells with low proteasomeactivity translated into increased self-renewal capacity.
UM-SCC-6 and UM-SCC-12 were cultured as mono-
layers or tumorspheres and irradiated with 5 daily frac-
tions of 3 Gy followed by a typical weekend gap of
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into ultra-low adhesions plates in sphere media. After
15 days, tumor spheres were counted. In both cell lines,
irradiation caused a significant increase in self-renewal
capacity for cells cultured as monolayers or tumorspheres
(Monolayers: UM-SCC6, 0 Gy: 1.85 ± 0.28, 5×3 Gy: 6.434 ±
0.25, p = 0.007, n = 2; UM-SCC12: 0 Gy: 1.2 ± 0.03%, 5×3
Gy: 3.87 ± 0.29% p = 0.012, n = 2; Spheres: UM-SCC6, 0 Gy:
1.78 ± 0.45%, 5×3 Gy: 8.05 ± 0.59%, p = 0.014, n = 2; UM-
SCC12, 0 Gy: 1.44 ± 0.17, 5×3 Gy: 3.65 ± 0.62% p = 0.075,
n = 2, two-sided Student’s t-test; Figure 2c and d).
Low proteasome subunit expression in HNSCC cells
predicts treatment outcome
In order to test the clinical significance of cells with de-
creased proteasome activity in HNSCCs we used a tis-
sue microarray that contained tumor samples of 82
HNSCC cases treated with primary definitive radiother-
apy or radiochemotherapy. We previously described that
lack of staining for the 19S proteasome regulatory sub-
unit PSMD1 correlates with lack of 26S proteasome
activity [21,25].
Figure 3a shows representative staining for levels 1–3
and Table 1 presents clinical data of patients by PSMD1-
score. Characteristics of all three patient groups were
quite similar. Possible imbalances in regards to tumor
site, nodal involvement, erythropoietin receptor [32] or
radiation may – if at all - favor patients with weak PSMD1-
expression scores.
Kaplan-Meier estimates show that patients who under-
went radiotherapy for macroscopic tumor and whose
tumor cells exhibited weak or intermediate, as opposed
to strong PSMD1 expression, had a decreased median
overall survival probability (21.2 vs 28.8 vs 43.8 months,
log-rank, p = 0.05) (Figure 3b). Comparably, a trend
was observed for time to local tumor progression
within the irradiated volume (p = 0.08, Figure 3c). This
suggested that the number of cancer stem cells present
during radiation treatment had an impact on treatment
outcome.
In the case of patients in which the tumors could be
resected successfully, expression of the proteasome sub-
unit PSMD1 in cancer cells before surgery did not cor-
relate with survival (Figure 3d). A description of these
patients is given in Table 2.
Discussion
We had previously reported that breast cancer [16] and
glioma [21] cells with intrinsically low proteasome activ-
ity have a CSC phenotype. Similar results were reported
for NSCLC [33] and pancreatic cancer [34]. Interest-
ingly, in prostate cancer [35], breast cancer [16,36], and
glioma [21,25] cells with low proteasome activity are
radioresistant and patients with breast cancers [37] orgliomas [25] that express low levels of proteasome sub-
units have an unfavorable outcome. Recently, we re-
ported that activation of the developmental Notch
signaling pathway links the CSC phenotype with the
proteasome. Musashi, a RNA binding protein crucial for
maintaining Notch signaling, binds to the 3’-UTR of
NF-YA mRNA, the master regulator of mammalian pro-
teasome subunit expression, thereby down-regulating
the proteasome in CSCs [38]. The intrinsic low prote-
asome activity in CSCs parallels with metabolic changes
[25] and up-regulation of free radical scavenger systems,
which ultimately cause radioresistance [17,36].
In the present study we show that HNSCC also con-
tains a population of cells with low proteasome activity
and decreased proteasome subunit expression and that
these cells have a CSC phenotype defined by operational
means. Like in breast cancer [16] or glioma [21], radi-
ation enriches for these cells by selectively killing the
more radiosensitive population with high proteasome ac-
tivity and lower self-renewing capacity.
To our knowledge we show here for the first time
that the number of cells with low proteasome activity
present in HNSCCs inversely correlates with the over-
all survival of patients suffering from HNSCC. It is
unlikely that design, conduct or patient selection con-
tributed to this finding. The clinical samples were de-
rived from prospective trials where data collection,
validation, and processing followed good clinical practice;
the adherence to study protocols was ascertained and a
continuous follow-up for nine years sufficiently substanti-
ates our observation. Although the sample size is limited,
essential methodological pitfalls seem not to confound
our observations. Baseline and treatment characteristics
are reasonably balanced, immune-histochemical process-
ing is standardized by TMA-methodology, adequate
controls were used, and two unbiased, independent re-
searchers, blinded for all clinical parameters, performed
the evaluation.
PSMD1 expression seemed to also affect the locore-
gional cancer control probability of our patients under-
going primary definitive radiotherapy and we propose
that treatment outcome was predominantly driven by
an impaired treatment efficacy based on an increased
number of therapy resistant CSCs. Furthermore, our
in vitro data suggested that radiation enriches for
CSCs and increases self-renewal capacity of HNSCC
cell populations. Finally, the number of CSCs in pa-
tients in which the tumor could be resected was not
related to the prognosis (Table 2 and Figure 3), thus
supporting the relevance of the total number of CSCs
for overall survival. One can speculate that the very
low number of CSCs in subclinical disease in those
patients will most likely be controlled by standard
radiotherapy regimens.
Figure 3 Level of PSDM1 expression correlates with treatment outcome. HNSCC tissue micro arrays were stained for PSMD1 to evaluate the
expression of this proteasome subunit. The intensity of the staining was evaluated independently by two pathologists. (a) Pictures of representative
staining for PSMD1 show the 3 different levels of staining. Overall survival (b) and loco-regional control (c) for patients receiving primary definitive
radiotherapy. (d) Overall survival for patients receiving postoperative radiotherapy.
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We conclude that HNSCCs contain subpopulations of
cells with CSC features, which can be identified by lack
of proteasome activity and low proteasome subunitPSMD1-expression. HNSCC CSCs are of clinical rele-
vance because they affect tumor control and survival.
Thus, PSMD1-testing could be useful in identifying pa-
tients with HNSCC at risk for relapse.
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